1. Home
  2. CAPR vs VSECU Comparison

CAPR vs VSECU Comparison

Compare CAPR & VSECU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$19.50

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo VSE Corporation Tangible Equity Units

VSECU

VSE Corporation Tangible Equity Units

N/A

Current Price

$51.20

Market Cap

1.6B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CAPR
VSECU
Founded
2005
N/A
Country
United States
United States
Employees
N/A
1600
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.6B
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
CAPR
VSECU
Price
$19.50
$51.20
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$44.63
N/A
AVG Volume (30 Days)
1.7M
23.8K
Earning Date
05-12-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.30
$38.45
52 Week High
$40.37
$68.10

Technical Indicators

Market Signals
Indicator
CAPR
VSECU
Relative Strength Index (RSI) 28.96 44.17
Support Level $5.25 $44.69
Resistance Level $30.39 $58.94
Average True Range (ATR) 1.33 2.05
MACD -0.26 -0.85
Stochastic Oscillator 16.93 0.00

Price Performance

Historical Comparison
CAPR
VSECU

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About VSECU VSE Corporation Tangible Equity Units

VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.

Share on Social Networks: